Sugi Predict

Sugi Predict / Compounds / SCHEMBL342698

SCHEMBL342698

SCHEMBL342698

Cn1ccnc1C(=O)c1cc(Cl)ccc1N

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CCR9 P51686 1/20 0.53
▸ RECQL P46063 1/20 0.49
▸ TSHR P16473 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ GRM1 Q13255 2/20 0.44
▸ GRM4 Q14833 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ GCK P35557 1/20 0.43
▸ HTT P42858 2/20 0.42
▸ NOS2 P35228 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ FADS1 O60427 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ LDHA P00338 1/20 0.41
▸ LDHB P07195 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14419394 0.84 CCR9 (0.54) CCR9TSHRRAB9AGRM1GRM4
SCHEMBL8550607 0.82 TSHR (0.50) TSHRRAB9ASMN1; SMN2HTTHSD17B10
SCHEMBL14419393 0.81 CCR9 (0.59) CCR9GRM1GRM4ALDH1A1LMNA
SCHEMBL7076703 0.78 HTT (0.45) CCR9TSHRRAB9AGRM1GRM4
SCHEMBL5918187 0.76 LDHA (0.60) CCR9TSHRRAB9ASMN1; SMN2HTT
SCHEMBL343131 0.76 RECQL (0.50) RECQLRAB9ASMN1; SMN2GCKNOS2
SCHEMBL9540049 0.75 RECQL (0.79) RECQLTSHRRAB9ASMN1; SMN2GCK
SCHEMBL343781 0.74 RECQL (0.58) CCR9RECQLTSHRRAB9AGRM4
SCHEMBL344480 0.73 HTT (0.60) RECQLRAB9ASMN1; SMN2GCKHTT
SCHEMBL7076440 0.73 MAPK14 (0.61) CCR9TSHRRAB9AGRM1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 — — US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 — — US disclosed
US-20170369483-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2017-12-28 — — US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 — — US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 — — US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 — — US disclosed
EP-1798223-B2 Aryl sulfonamides CHEMOCENTRYX INC (US) 2014-07-30 — — EP disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 — — US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 — — US disclosed
EP-1798223-A2 Aryl sulfonamides ChemoCentryx Inc (US) 2007-06-20 — — EP disclosed
US-20060111351-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2006-05-25 — — US disclosed
WO-2005112925-A1 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2005-12-01 — — WO disclosed
US-6939885-B2 Aryl sulfonamides CHEMOCENTRYX (US) 2005-09-06 — — US disclosed
EP-1562940-A2 ARYL SULFONAMIDES ChemoCentryx Inc (US) 2005-08-17 — — EP disclosed
US-20050165067-A1 Aryl sulfonamides CHEMOCENTRYX 2005-07-28 — — US disclosed
US-20050137193-A1 Aryl sulfonamides CHEMOCENTREYX 2005-06-23 — — US disclosed
US-20040171654-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2004-09-02 — — US disclosed
WO-2004046092-A2 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137193-A1 Aryl sulfonamides CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-20060111351-A1 Aryl sulfonamides CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-20170369483-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-20040171654-A1 Aryl sulfonamides CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-20050165067-A1 Aryl sulfonamides CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885
US-20130267492-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 CCR9 1/4885RECQL 4746/4885TSHR 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.